DE19701619A1 - Verwendung von Pramipexol zur Behandlung des restless legs syndroms - Google Patents

Verwendung von Pramipexol zur Behandlung des restless legs syndroms

Info

Publication number
DE19701619A1
DE19701619A1 DE19701619A DE19701619A DE19701619A1 DE 19701619 A1 DE19701619 A1 DE 19701619A1 DE 19701619 A DE19701619 A DE 19701619A DE 19701619 A DE19701619 A DE 19701619A DE 19701619 A1 DE19701619 A1 DE 19701619A1
Authority
DE
Germany
Prior art keywords
pramipexole
restless legs
legs syndrome
treat restless
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19701619A
Other languages
English (en)
Other versions
DE19701619B4 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE19701619A priority Critical patent/DE19701619B4/de
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to HU0001913A priority patent/HU226564B1/hu
Priority to CA002275379A priority patent/CA2275379C/en
Priority to EP98903378A priority patent/EP0989850B1/de
Priority to ES98903378T priority patent/ES2231959T3/es
Priority to SK920-99A priority patent/SK284264B6/sk
Priority to DE69827387T priority patent/DE69827387T2/de
Priority to NZ336804A priority patent/NZ336804A/xx
Priority to NZ510007A priority patent/NZ510007A/en
Priority to AT98903378T priority patent/ATE281165T1/de
Priority to KR1020057012562A priority patent/KR100761774B1/ko
Priority to PL334498A priority patent/PL190898B1/pl
Priority to PCT/US1998/000216 priority patent/WO1998031362A1/en
Priority to CZ19992478A priority patent/CZ289863B6/cs
Priority to RO99-00818A priority patent/RO120757B1/ro
Priority to CN98801721A priority patent/CN1117564C/zh
Priority to PT98903378T priority patent/PT989850E/pt
Priority to RU99118211/14A priority patent/RU2192252C2/ru
Priority to AU60168/98A priority patent/AU723119B2/en
Priority to SI9820013A priority patent/SI20060A/sl
Priority to SI9830725T priority patent/SI0989850T1/xx
Priority to JP53336998A priority patent/JP4406685B2/ja
Priority to KR1019997006461A priority patent/KR20000070234A/ko
Priority to ZA9800420A priority patent/ZA98420B/xx
Publication of DE19701619A1 publication Critical patent/DE19701619A1/de
Priority to BG103543A priority patent/BG64614B1/bg
Priority to NO19993360A priority patent/NO321151B1/no
Priority to FI991616A priority patent/FI120135B/fi
Priority to US09/427,809 priority patent/US6194445B1/en
Priority to HK00103742A priority patent/HK1024408A1/xx
Application granted granted Critical
Publication of DE19701619B4 publication Critical patent/DE19701619B4/de
Priority to JP2008272286A priority patent/JP2009062388A/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Semiconductor Memories (AREA)
  • Liquid Crystal Substances (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Corsets Or Brassieres (AREA)

Description

Die vorliegende Erfindung betrifft die Verwendung von 2-Amino-6-n-propylamino- 4,5,6,7-tetrahydrobenzo-thiazol, seinem (+)- oder (-)-Enantiomer oder dessen pharmakologisch verträgliche Salze zur Behandlung des restless legs syndroms.
Pramipexol - das 2-Amino-6-n-propylamino-4,5,6,7-tetrahydrobenzo-thiazol­ dihydrochlorid - ist ein Dopamine - D2/D2 Agonist dessen Synthese in dem europäischen Patent 186 087 beschrieben ist. Pramipexol ist in erster Linie zur Behandlung der Schizophrenie und insbesondere zur Behandlung des Parkinsons bekannt. Aus der deutschen Patentanmeldung DE 38 43 227 ist offenbart, daß Pramipexol den Prolactinserumspiegel senkt, weiterhin ist aus der deutschen Patentanmeldung DE 39 33 738 bekannt, Pramipexol zur Senkung hoher TSH- Spiegel einzusetzen. Die transdermale Applikation ist in dem US-Patent 51,112,842 offenbart, und die WO Patentanmeldung PCT/EP93/03389 beschreibt die Verwendung von Pramipexol als Antidepressivum.
Es wird vorgeschlagen 2-Amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol­ insbesondere Pramipexol zur Behandlung des restless legs syndroms.
Eine wirksame Dosis liegt im Bereich zwischen 0.05 und 10 mg, bevorzugt zwischen 0.1 und 6 besonders bevorzugt zwischen 0.75 und 4.5 mg/Tag und Patient. Die Applikation erfolgt überlicherweise in 3 bis 4 Einzelgaben. Die Applikation kann oral, intravenös, transdermal, parenteral oder durch Inhalation erfolgen, bevorzugt ist die orale Applikation.
Galenische Zubereitungen sind aus dem Stand der Technik bekannt, beispielsweise in Form von Tabletten, Dragées, Suppositorien, Lösungen für die Injektion oder Tropfen.

Claims (5)

1. Verwendung von 2-Amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol, seinem (-)- oder (+)-Enantiomer, sowie seiner pharmakologisch verträglichen Salze zur Behandlung des restless legs syndromes.
2. Verwendung nach Anspruch 1 in einer Dosierung von 0.05 bis 10 mg pro Tag und Patient.
3. Verwendung nach Anspruch 1 in einer Dosierung von 0.75 bis 4.5 mg pro Tag und Patient.
4. Arzneimittelzubereitung, gekennzeichnet durch einen Gehalt von 1 mg Pramipexol.
5. Arzneimittelzubereitung, gekennzeichnet durch einen Gehalt von 0.25 mg Pramipexol.
DE19701619A 1997-01-17 1997-01-17 Verwendung von Pramipexol zur Behandlung des restless legs syndroms Expired - Lifetime DE19701619B4 (de)

Priority Applications (30)

Application Number Priority Date Filing Date Title
DE19701619A DE19701619B4 (de) 1997-01-17 1997-01-17 Verwendung von Pramipexol zur Behandlung des restless legs syndroms
AU60168/98A AU723119B2 (en) 1997-01-17 1998-01-16 Use of pramipexole in the treatment of restless legs syndrome
EP98903378A EP0989850B1 (de) 1997-01-17 1998-01-16 Verwendung von pramipexol zur behandlung von restless-legs-syndrom
ES98903378T ES2231959T3 (es) 1997-01-17 1998-01-16 Uso de pramipexol para el tratamiento del sindrome de piernas inquietas.
RU99118211/14A RU2192252C2 (ru) 1997-01-17 1998-01-16 Применение прамипексола в лечении синдрома усталых ног
DE69827387T DE69827387T2 (de) 1997-01-17 1998-01-16 Verwendung von pramipexol zur behandlung des restless-legs-syndroms
NZ336804A NZ336804A (en) 1997-01-17 1998-01-16 Use of pramipexole in the treatment of restless legs syndrome
CA002275379A CA2275379C (en) 1997-01-17 1998-01-16 Use of pramipexole in the treatment of restless legs syndrome
AT98903378T ATE281165T1 (de) 1997-01-17 1998-01-16 Verwendung von pramipexol zur behandlung von restless-legs-syndrom
SI9820013A SI20060A (sl) 1997-01-17 1998-01-16 Uporaba pramipeksola v zdravljenju sindroma nemirnih nog
PL334498A PL190898B1 (pl) 1997-01-17 1998-01-16 Nowe zastosowanie pramipeksolu
PCT/US1998/000216 WO1998031362A1 (en) 1997-01-17 1998-01-16 Use of pramipexole in the treatment of restless legs syndrome
CZ19992478A CZ289863B6 (cs) 1997-01-17 1998-01-16 Léčivo pro léčení syndromu neklidných nohou
RO99-00818A RO120757B1 (ro) 1997-01-17 1998-01-16 Utilizarea pramipexolului în tratamentul sindromului picioarelor neliniştite
CN98801721A CN1117564C (zh) 1997-01-17 1998-01-16 普拉克索在治疗多动腿综合征中的用途
PT98903378T PT989850E (pt) 1997-01-17 1998-01-16 Utilizacao de pramipexole no tratamento da sindroma das pernas inquietas
HU0001913A HU226564B1 (en) 1997-01-17 1998-01-16 Use of pramipexole for the preparation of pharmaceutical compositions treating restless legs syndrome
NZ510007A NZ510007A (en) 1997-01-17 1998-01-16 Use of pramipexole in the treatment of restless legs syndrome
KR1020057012562A KR100761774B1 (ko) 1997-01-17 1998-01-16 프라미펙솔의 하지 불안 증후군 치료 용도
SI9830725T SI0989850T1 (en) 1997-01-17 1998-01-16 Use of pramipexole in the treatment of restless legs syndrome
JP53336998A JP4406685B2 (ja) 1997-01-17 1998-01-16 不穏下肢症候群の治療におけるプラミペキソールの使用
KR1019997006461A KR20000070234A (ko) 1997-01-17 1998-01-16 프라미펙솔의 하지 불안 증후군 치료 용도
SK920-99A SK284264B6 (sk) 1997-01-17 1998-01-16 Liečivo na liečenie syndrómu nepokojných nôh
ZA9800420A ZA98420B (en) 1997-01-17 1998-01-19 Use of pramipexole in the treatment of restless legs syndrome.
BG103543A BG64614B1 (bg) 1997-01-17 1999-07-01 Използване на прамипексол при лечение на синдрома на неспокойни крака
NO19993360A NO321151B1 (no) 1997-01-17 1999-07-07 Anvendelse av 2-amino-6-n-propyl-4,5,6,7-tetrahydrobenzotiazol, dets (-)-enantiomer eller et farmasoytisk akseptabelt salt av disse, for fremstilling av et medikament for behandling av "restless leg"- syndromet hos en pasient som lider eller mistenkes a ha denne tilstand
FI991616A FI120135B (fi) 1997-01-17 1999-07-16 Pramipeksolin käyttö lääkkeen, joka on tarkoitettu levottomien jalkojen oireyhtymän hoitamiseen, valmistamiseksi
US09/427,809 US6194445B1 (en) 1997-01-17 1999-10-27 Use of pramipexole in the treatment of restless legs syndrome
HK00103742A HK1024408A1 (en) 1997-01-17 2000-06-21 Use of pramipexole in the treatment of restless legs syndrome
JP2008272286A JP2009062388A (ja) 1997-01-17 2008-10-22 不穏下肢症候群の治療におけるプラミペキソールの使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19701619A DE19701619B4 (de) 1997-01-17 1997-01-17 Verwendung von Pramipexol zur Behandlung des restless legs syndroms

Publications (2)

Publication Number Publication Date
DE19701619A1 true DE19701619A1 (de) 1998-07-23
DE19701619B4 DE19701619B4 (de) 2007-10-11

Family

ID=7817708

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19701619A Expired - Lifetime DE19701619B4 (de) 1997-01-17 1997-01-17 Verwendung von Pramipexol zur Behandlung des restless legs syndroms
DE69827387T Expired - Lifetime DE69827387T2 (de) 1997-01-17 1998-01-16 Verwendung von pramipexol zur behandlung des restless-legs-syndroms

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69827387T Expired - Lifetime DE69827387T2 (de) 1997-01-17 1998-01-16 Verwendung von pramipexol zur behandlung des restless-legs-syndroms

Country Status (24)

Country Link
EP (1) EP0989850B1 (de)
JP (2) JP4406685B2 (de)
KR (2) KR20000070234A (de)
CN (1) CN1117564C (de)
AT (1) ATE281165T1 (de)
AU (1) AU723119B2 (de)
BG (1) BG64614B1 (de)
CA (1) CA2275379C (de)
CZ (1) CZ289863B6 (de)
DE (2) DE19701619B4 (de)
ES (1) ES2231959T3 (de)
FI (1) FI120135B (de)
HK (1) HK1024408A1 (de)
HU (1) HU226564B1 (de)
NO (1) NO321151B1 (de)
NZ (2) NZ510007A (de)
PL (1) PL190898B1 (de)
PT (1) PT989850E (de)
RO (1) RO120757B1 (de)
RU (1) RU2192252C2 (de)
SI (1) SI20060A (de)
SK (1) SK284264B6 (de)
WO (1) WO1998031362A1 (de)
ZA (1) ZA98420B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013902A2 (de) * 1999-08-19 2001-03-01 Boehringer Ingelheim Pharma Kg Wirkstoffkombination enthaltend clonidin und pramipexol

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001861A (en) 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
DE19701619B4 (de) * 1997-01-17 2007-10-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Pramipexol zur Behandlung des restless legs syndroms
SE9803760D0 (sv) * 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
CA2626249A1 (en) * 2005-10-18 2007-04-26 Boehringer Ingelheim International Gmbh Use of pramipexol for treating moderate to severe restless legs syndrome (rls)
NZ571591A (en) * 2006-04-03 2011-09-30 Teva Pharma Use of rasagiline for the treatment of restless legs syndrome
TR200906997A1 (tr) 2009-09-11 2011-03-21 Sanovel �La� San. Ve T�C. A. �. Pramipeksol farmasötik bileşimleri.
TR200907554A1 (tr) 2009-10-06 2011-04-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Oral yolla dağılan pramıpexole bileşimleri.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572485D1 (en) * 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
DE3843227A1 (de) * 1988-12-22 1990-07-05 Boehringer Ingelheim Kg Neue verwendung von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzthiazol
DE3933738A1 (de) * 1989-10-10 1991-04-11 Boehringer Ingelheim Kg Neue verwendung von 2-aminothiazol-derivaten (tsh)
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
DE4125446A1 (de) * 1991-08-01 1993-02-04 Uwe Dipl Ing Behmann Verfahren und einrichtung zur elektrischen kurzschlusspruefung und -ortung fuer leitungen, insbesondere fuer fahrleitungen elektrischer bahnen
US5598352A (en) * 1994-09-30 1997-01-28 Cirrus Logic, Inc. Method and apparatus for audio and video synchronizing in MPEG playback systems
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
DE19701619B4 (de) * 1997-01-17 2007-10-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Pramipexol zur Behandlung des restless legs syndroms

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013902A2 (de) * 1999-08-19 2001-03-01 Boehringer Ingelheim Pharma Kg Wirkstoffkombination enthaltend clonidin und pramipexol
WO2001013902A3 (de) * 1999-08-19 2001-08-23 Boehringer Ingelheim Pharma Wirkstoffkombination enthaltend Clonidin und Pramipexol

Also Published As

Publication number Publication date
HUP0001913A2 (hu) 2000-11-28
NZ336804A (en) 2001-03-30
FI120135B (fi) 2009-07-15
JP4406685B2 (ja) 2010-02-03
KR100761774B1 (ko) 2007-10-04
FI991616A (fi) 1999-07-16
ES2231959T3 (es) 2005-05-16
EP0989850A1 (de) 2000-04-05
HK1024408A1 (en) 2000-10-13
SK92099A3 (en) 2000-08-14
PT989850E (pt) 2004-12-31
NZ510007A (en) 2004-11-26
CN1243439A (zh) 2000-02-02
CN1117564C (zh) 2003-08-13
SK284264B6 (sk) 2004-12-01
PL190898B1 (pl) 2006-02-28
EP0989850B1 (de) 2004-11-03
BG103543A (en) 2000-04-28
NO321151B1 (no) 2006-03-27
KR20000070234A (ko) 2000-11-25
ATE281165T1 (de) 2004-11-15
JP2009062388A (ja) 2009-03-26
RO120757B1 (ro) 2006-07-28
NO993360D0 (no) 1999-07-07
CA2275379A1 (en) 1998-07-23
NO993360L (no) 1999-07-07
BG64614B1 (bg) 2005-09-30
KR20050085947A (ko) 2005-08-29
CZ289863B6 (cs) 2002-04-17
DE19701619B4 (de) 2007-10-11
ZA98420B (en) 1999-07-19
RU2192252C2 (ru) 2002-11-10
HU226564B1 (en) 2009-04-28
AU6016898A (en) 1998-08-07
CA2275379C (en) 2006-11-28
AU723119B2 (en) 2000-08-17
DE69827387D1 (de) 2004-12-09
WO1998031362A1 (en) 1998-07-23
JP2001511158A (ja) 2001-08-07
PL334498A1 (en) 2000-02-28
DE69827387T2 (de) 2005-10-27
HUP0001913A3 (en) 2002-09-30
CZ247899A3 (cs) 2000-01-12
SI20060A (sl) 2000-04-30

Similar Documents

Publication Publication Date Title
DE60035232T2 (de) (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
DE69530606T2 (de) Verwendung von pramipexole als neuroschutzmittel
DE60218703T2 (de) (-)-1-(3,4-dichlorphenyl)-3-azabicyclo ä3.1.0ühexan, zusammensetzungen davon und verwendung als dopamin-wiederaufnahme-hemmer
DE60119896T2 (de) Verwendung von pramipexol zur behandlung von tabak/nikotin abhängigkeit
EP0675717B1 (de) Verwendung von 2-amino-6-a-propyl-amino-4,5,6,7-tetrahydrobenzothiazol (pramipexol) als arzneimittel mit antidepressiver wirkung
DK2389937T3 (en) Medical composition to improve brain function
EP1940398A1 (de) Verwendung von pramipexol zur behandlung des moderaten bis schweren restless legs syndroms (rls)
DE60009697T2 (de) Verwendung von 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazin und dessen physiologisch akzeptablen salzen zur behandlung von bipolaren krankheiten und manie
DE3406533A1 (de) Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
BR0312216A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito que sofre de uma doença ou condição patológica e combinação de produto
EP1093369A2 (de) Mittel mit antidepressiver wirkung, enthaltend pramipexol und ein weiteres antidepressivum
DE19701619A1 (de) Verwendung von Pramipexol zur Behandlung des restless legs syndroms
DE60122015T2 (de) Behandlung affektiver störungen durch kombinierte wirkung eines nikotinischen rezeptoragonisten und einer monoaminergischen substanz
Rènyi Ejaculations induced by p-chloroamphetamine in the rat
DE69918972T2 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE19758564A1 (de) Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung
US5011841A (en) Treatment of depression
Ross et al. Structural requirements for uptake into serotoninergic neurones
DE2206570A1 (de) Heilmittel zur Behandlung von Leber affektionen
CH683395A5 (de) Verwendung von Catechol-O-methyl-transferase-Inhibitoren und von deren physiologisch verträglichen Salzen und Estern.
JPH0259520A (ja) 偏頭痛の治療のための（ｓ）‐エモパミル
KR930000049B1 (ko) 세트랄린을 사용한 화학약품 의존성의 치료방법
DE1793383B2 (de) 4-Cyan-4-phenyl-aminocyclohexane und deren wasserlösliche Salze, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3525390A1 (de) Verwendung von (alpha)-dihydroergokryptin zur behandlung des parkinson-syndroms, von depressionen und zephalalgien
EP0161501A1 (de) Antiulcermittel zur Behandlung von Geschwüren

Legal Events

Date Code Title Description
8181 Inventor (new situation)

Free format text: MEIER, DIETER, DR., 65185 WIESBADEN, DE OERTEL, WOLFGANG H., PROF. DR., ., ZZ GOMEZ-MANCILLA, BALTAZAR, DR., PORTAGE, MICH., US MONTPLAISIR, JACQUES, DR., MONTREAL, QUEBEC, CA

8181 Inventor (new situation)

Free format text: MEIER, DIETER, DR., 65185 WIESBADEN, DE OERTEL, WOLFGANG H., PROF. DR., ., ZZ GOMEZ-MANCILLA, BALTAZAR, DR., PORTAGE, MICH., US MONTPLAISIR, JACQUES, DR., MONTREAL, QUEBEC, CA

8181 Inventor (new situation)

Free format text: MEIER, DIETER, DR., 65185 WIESBADEN, DE OERTEL, WOLFGANG H., PROF. DR., 35282 RAUSCHENBERG, DE GOMEZ-MANCILLA, BALTAZAR, DR., PORTAGE, MICH., US MONTPLAISIR, JACQUES, DR., MONTREAL, QUEBEC, CA

8127 New person/name/address of the applicant

Owner name: BOEHRINGER INGELHEIM PHARMA KG, 55218 INGELHEIM, D

8128 New person/name/address of the agent

Representative=s name: LAUDIEN, D., DIPL.-CHEM. DR.PHIL.NAT., PAT.-ANW.,

8127 New person/name/address of the applicant

Owner name: PHARMACIA & UPJOHN CO., KALAMAZOO, MICH., US

Owner name: BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG, 55218 IN

8110 Request for examination paragraph 44
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, 552, DE

R071 Expiry of right